Skip to content

Nasotracheal Intubation in Critically Ill.

Nasotracheal Intubation Vs. Conventional Airway Management in Critically Ill Patients.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05780385
Acronym
NaTra-P
Enrollment
126
Registered
2023-03-22
Start date
2023-02-10
Completion date
2024-11-08
Last updated
2025-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Critical Care, Tracheal Intubation Morbidity

Keywords

tracheal intubation, airway management, critical care, nasotracheal intubation

Brief summary

The aim of this prospective randomized trail is to compare nasotracheal versus orotracheal intubation in critically ill patients. We aim to study: * required sedation depth * rate of spontaneous breathing * extend and possibility of physiotherapy * vasopressor and sedative drug doses Participants are randomized 1:1 to receive either nasotracheal or orotracheal intubation.

Detailed description

In the intensive care unit endotracheal intubation and consecutive mechanical ventilation are required for different surgical procedures, examinations and interventions in the ICU or due to respiratory insufficiency. Commonly, intubation is performed orotracheally by direct laryngoscopy after preoxygenation and administration of narcotics and a muscle relaxant. When using this technique sedation is often necessary for tolerance of the orotracheal tube. To avoid the adverse side effects of sedation and mechanical ventilation as for example hypotension, barotrauma, ventilator associated pneumonia, etc., intubation via a nasotracheal approach might be favorable. Retrospective data show that nasotracheal intubation is associated with fewer sedatives, vasopressors, and a higher rate of spontaneous breathing. As there is a paucity of data concerning the use of nasotracheal intubation in the intensive care setting the investigators aim to compare the use of orotracheal and nasotracheal tubes in a prospective randomized trial, using sedation depth as primary outcome measure.

Interventions

DEVICEnasotracheal intubation

patients requiring tracheal intubation receive nasotracheal intubation

DEVICEorotracheal intubation

patients requiring tracheal intubation receive orotracheal intubation

Sponsors

Universitätsklinikum Hamburg-Eppendorf
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 * Patients requiring tracheal intubation during their intensive care stay.

Exclusion criteria

* orotracheal or nasotracheal route of intubation technically not possible (e.g. confirmed indication for awake fiberoptic intubation due to expected difficult airway) * tracheal intubation indicated for deep sedation (e.g. treatment of elevated intracranial pressure) * thrombocytopenia \< 50/nl or other risk factors for bleeding * pregnant or breastfeeding women * denial of consent

Design outcomes

Primary

MeasureTime frameDescription
Sedation depthintubation to 72 hoursfraction of time with a Richmond Agitation and Sedation Scale (RASS) of 0 or -1. Range -5 to +4 with 0 as optimum value representing awake and alert patient.

Secondary

MeasureTime frameDescription
time to extubationintubation to day 30time until airway device can be removed or patient receives tracheostomy
rate of extubationintubation to day 30rate of successful removal of airway device without tracheostomy
tracheostomyintubation to day 30rate of tracheostomy
spontaneous breathingintubation to day 10rate of spontaneous breathing while on airway device
vasopressor therapyintubation to day 10doses of vasopressor drugs while on airway device
sedative drugsintubation to day 10doses of sedative drugs therapy while on airway device
Sedation depthintubation to day 10fraction of time with Richmond Agitation and Sedation Scale (RASS) above and below targeted RASS of 0 or -1. Range -5 to +4 with 0 as optimum value representing awake and alert patient.
sinusitisintubation to day 30incidence of sinusitis associated with airway device
physiotherapyintubation to day 10intensive care unit mobility score (ICU-MS), Range 0 to 10 with higher values indicating higher extend of physiotherapy
length of intensive care stayintubation to day 30length of intensive care stay
complicationsintubation to day 1complications associated with intubation (i.e. bleeding, damage to teeth, aspiration)
mortalityintubation to day 30mortality
ventilator associated pneumoniaintubation to day 30incidence of ventilator associated pneumonia associated with airway device

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026